Compare SSTI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTI | MCRB |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.4M | 85.7M |
| IPO Year | 2017 | 2015 |
| Metric | SSTI | MCRB |
|---|---|---|
| Price | $6.85 | $8.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $15.00 | $14.00 |
| AVG Volume (30 Days) | ★ 75.7K | 36.6K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $34,753,000.00 | $789,000.00 |
| Revenue This Year | $7.43 | N/A |
| Revenue Next Year | $6.25 | N/A |
| P/E Ratio | ★ N/A | $13.38 |
| Revenue Growth | ★ 46.25 | N/A |
| 52 Week Low | $5.78 | $6.64 |
| 52 Week High | $16.92 | $29.98 |
| Indicator | SSTI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 43.31 |
| Support Level | $6.05 | $8.08 |
| Resistance Level | $6.87 | $9.53 |
| Average True Range (ATR) | 0.29 | 0.53 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 61.79 | 29.58 |
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes: ShotSpotter, the acoustic gunshot detection system; CrimeTracer, the foremost law enforcement search engine; CaseBuilder, a one-stop investigation management system; ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact; PlateRangerTM powered by Rekor, an automatic license plate recognition ("ALPR") and vehicle identification solution; SafePointe, an AI-based weapons detection system.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.